Last reviewed · How we verify
NCT06666842
Longitudinal Effects of a Commercial Digital Weight Management Program on Weight Loss
NA trial testing Noom Weight in Obesity in 412 participants. Completed in 1 December 2023.
1 December 2022
Quick facts
| Lead sponsor | Noom Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 412 |
| Start date | 1 June 2022 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Noom Weight
- Educational Control
Conditions studied
- Obesity — all drugs for Obesity →
- Weight Loss — all drugs for Weight Loss →
Sponsor
Noom Inc.
Who can join
Adults 18 to 75, any sex, with Obesity or Weight Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized controlled trial (RCT) will test how well a fully remote weight management program (Noom Weight) helps adults with overweight or obesity (BMI 25-45) achieve weight loss in both the short-term (16 weeks) and the long-term (68 weeks), compared to an educational program). Participants will be randomly assigned to use the 16-week Noom Weight program or receive weekly emails with weight loss-related tips and information. Weight will be measured at baseline, 16, 29, 42, and 68 weeks. Changes in physical activity, eating disorder risk, and body appreciation will also be assessed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06666842
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Noom Inc. trials
Trials by the same sponsor.
- NCT05015491 — Effects of Online App Weight Loss Programs on Liver Health in Obese Adults · NA · completed
- NCT04967209 — Investigation of a Digital Healthy Habits Program for Individuals With Breast Cancer · completed
- NCT04871295 — Improving Quality of Life in Men and Women With Overweight or Obesity · NA · completed
- NCT04753268 — Mobile Behavior Change Program for Weight Loss in Breast Cancer Survivors · NA · completed
- NCT04645108 — Coached or Non-Coached Weight Loss Intervention · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06666842 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Noom Inc.
- Last refreshed: 31 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06666842.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing